International Goals

Eliminate viral hepatitis as a major public health threat by 2030. Reduce infections to less than one million and deaths to 500,000 in the same time period.

MPP’s Contribution

Promote access to direct-acting antivirals with the potential of working across all strains of the virus.

Hepatitis C is a liver disease caused by the hepatitis C virus (HCV). Seventy-one million are estimated to be living with the virus, with 72% residing in low- and middle-income countries. According to the WHO, there were 1.75 million new infections in 2015[1].

New direct-acting antivirals (DAA) that are effective across all major HCV strains can cure millions. Yet, approximately 98,5% of the people infected with HCV are not receiving treatment[2].

We aim to license new and pipeline pan-genotypic DAAs for generic manufacture. We work with generic partners to speed the development and distribution of new HCV treatments that can eliminate the virus through a short course of oral therapy in regions with a high HCV burden. We signed our first licence for a hepatitis C treatment in 2015. A second licence was signed in November 2018.

Hepatitis B

The MPP licences for Gilead Sciences, covering tenofovir disoproxil fumarate (TDF) and tenofovir alafenamide (TAF), benefit people living with HIV as well as people living with chronic hepatitis B, a disease that affects 257 million globally[3]. The majority of people with hepatitis B live in low- and middle-income countries.

[1] World Health Organization, Hepatitis C Fact Sheet, July 2019 (last accessed on 3 Dec. 2019)

[2] World Health Organization, Global Hepatitis Report 2017

[3] World Health Organization, Hepatitis B Fact Sheet, July 2019 (last accessed on 3 Dec. 2019)

This website uses cookies to ensure you get the best experience on our website. Learn More